^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pimurutamab (HLX07)

    i
    Company:
    Fosun Pharma
    Drug class:
    EGFR inhibitor
    Related drugs:
    Apply
    Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC (NCT06542588)
    Phase 2
    Wuhan Union Hospital, China
    Recruiting
    Last update posted :
    12/18/2024
    Initiation :
    07/19/2024
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    BRAF
    |
    Hetronifly (serplulimab) • pimurutamab (HLX07)
    Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors (NCT04297995)
    Phase 2
    Shanghai Henlius Biotech
    Active, not recruiting
    Last update posted :
    08/08/2023
    Initiation :
    07/29/2020
    Primary completion :
    05/30/2024
    Completion :
    06/30/2025
    PD-L1 • PD-1
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • 5-fluorouracil • Hetronifly (serplulimab) • pimurutamab (HLX07)
    The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors. (HLX07Ib/II) (NCT03577704)
    Phase 1/2
    Shanghai Henlius Biotech
    Completed
    Last update posted :
    04/12/2023
    Initiation :
    08/08/2018
    Primary completion :
    09/30/2022
    Completion :
    12/30/2022
    PD-L1 • PD-1 • CTLA4 • IL2RA • TNFRSF9
    |
    cisplatin • carboplatin • gemcitabine • paclitaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • pimurutamab (HLX07)
    A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC (NCT05221658)
    Phase 2
    Shanghai Henlius Biotech
    Recruiting
    Last update posted :
    08/29/2022
    Initiation :
    08/25/2022
    Primary completion :
    06/30/2024
    Completion :
    08/30/2025
    EGFR
    |
    EGFR expression
    |
    cisplatin • 5-fluorouracil • Hetronifly (serplulimab) • pimurutamab (HLX07)
    A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression (NCT05215925)
    Phase 2
    Shanghai Henlius Biotech
    Not yet recruiting
    Last update posted :
    07/06/2022
    Initiation :
    02/01/2023
    Primary completion :
    07/15/2023
    Completion :
    08/10/2024
    EGFR
    |
    EGFR expression • EGFR overexpression
    |
    carboplatin • docetaxel • pemetrexed • pimurutamab (HLX07)
    A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC (NCT04976647)
    Phase 2
    Shanghai Henlius Biotech
    Recruiting
    Last update posted :
    05/06/2022
    Initiation :
    01/18/2022
    Primary completion :
    01/30/2023
    Completion :
    10/30/2024
    EGFR
    |
    albumin-bound paclitaxel • Hetronifly (serplulimab) • pimurutamab (HLX07)
    Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC (NCT05239650)
    Phase 2
    Shanghai Henlius Biotech
    Not yet recruiting
    Last update posted :
    05/03/2022
    Initiation :
    07/15/2022
    Primary completion :
    10/15/2025
    Completion :
    10/15/2026
    KRAS • BRAF
    |
    BRAF wild-type
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • Hetronifly (serplulimab) • pimurutamab (HLX07)
    HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer (NCT05246982)
    Phase 2
    Shanghai Henlius Biotech
    Recruiting
    Last update posted :
    05/02/2022
    Initiation :
    03/23/2022
    Primary completion :
    12/20/2023
    Completion :
    03/30/2024
    HER-2 • PD-L1
    |
    HER-2 negative • PD-L1 negative
    |
    capecitabine • oxaliplatin • Hetronifly (serplulimab) • pimurutamab (HLX07)